Next generation sequencing (NGS) has been an invaluable tool to put genomic sequencing into clinical practice. The incorporation of clinically relevant target sequences into NGS-based gene panel tests has generated practical diagnostic tools that enable individualized cancer-patient care. The clinical utility of gene panel testing includes investigation of the genetic basis for an individual's response to therapy, such as signaling pathways associated with a response to specific therapies, microsatellite instability and a hypermutated phenotype, and deficiency in the DNA doublestrand break repair pathway. In this review, we describe the concept of precision cancer medicine using target sequences in gene panel tests as well as the importance of the control of sample quality in routine NGS-based genomic testing. We describe geographic and ethnic differences in cancer genomes, and discuss issues that need to be addressed in the future based on our experiences in Japan.
| INTRODUC TI ON
Large-scale genomic studies, including The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) and the International Cancer Genome Consortium (ICGC; http://www.icgc.org/), have identified major driver-gene mutations in various types of solid tumors, [1] [2] [3] which have led to new therapeutic strategies for precision cancer medicine. [4] [5] [6] [7] [8] The main platform for TCGA and ICGC projects was whole exome sequencing (WES) utilizing next generation sequencing (NGS), which has provided comprehensive gene alteration data in protein-coding regions for all types of human cancer. 3 Next generation sequencing-based genomic sequencing has enabled the sequencing of individual cancer-patient genomes, and has become faster and less expensive year by year, such that NGS can be used, not only in research settings, but also in clinical practice. Sequencing the whole exome, let alone the whole genome, is technically possible given today's advanced technology; however, they provide more information than what can be practically analyzed and interpreted.
It is difficult to process this amount of data at a level required for clinical application, and it is too costly for individual patient diagnosis. Recently, NGS-based gene panel tests, in which only clinically important genes are examined, have been developed to obtain genomic data in a timely and cost-effective way based on the data learned from previous WES-based comprehensive studies. At present, the NGS-based gene panel test is the first choice for individual cancer-patient care, when introducing NGS technology into daily practice.
Whole exome sequencing or other types of genome-wide analysis have revealed geographic and ethnic diversity in the genetic alterations associated with cancer, 9, 10 which indicate that the efficacy of each drug and its side-effects might be different among populations.
However, most NGS data are from North America and Europe, and there has been a paucity of data for genetic alterations in Asian cancer patients. For example, only 5.5% of participants in the TCGA cohort are from populations of Asian ethnicity (http://cancergenome.
nih.gov/). It is therefore important to consider geographic and ethnic differences when looking to understand the profile of genomic alterations, and apply NGS analysis to the development of therapies for
Asian patients. Recently, we studied several types of solid cancers, including colorectal, gastric, lung, and breast cancer, in Japan utilizing NGS-based comprehensive genomic panel testing, 8, [11] [12] [13] [14] [15] [16] [17] [18] and revealed some differences in genomic alterations between Asian and non-Asian populations.
The current notion is that NGS-based genomic sequencing will realize "precision medicine", in which each patient receives individualized therapy based on their genetic alterations in the tumor.
Through experience, we have learned that control of sample quality is crucial when applying NGS-based genomic testing in daily practice. Moreover, we have learned that gene panel testing is a clinically useful approach to investigate the genomic mechanisms related to the therapies. These include therapy-related signaling pathways, microsatellite instability and a hypermutated phenotype, and deficiency in the DNA double-strand break repair pathways. In this review we therefore describe the concept of precision medicine and the utility of target sequencing using gene panel tests, based on our experience of research in a Japanese population.
| CON CEP T OF PRECIS I ON MED I CINE AND TARG E T S EQUEN CING
Precision medicine is to utilize an individual's genes, environment, and lifestyle to personalize the management of a disease. 5 Today, thanks to the advancement of genomic sequencing technology, it has become possible to determine the genomic changes related to disease in each individual patient. Former US president Barack Obama proposed the "Precision Medicine Initiative" in his State of the Union address in January 2015, specifically focusing on cancer as a target disease for treatment with precision medicine. Abundant time and effort have been devoted to determining the human and cancer genome that became the foundation of Obama's precision medicine initiative ( Figure 1 ). The Human Genome Project, which took more than 10 years to complete, revealed the entire map of a normal human genome. 19 Through this comprehensive project, it was recognized that cancer is a disease of the genome, and that it was important to examine changes over the cancer genome to overcome the disease. 20 Indeed, during the period of the sequencing of the human genome, cancer researchers identified the majority of important oncogenes and tumor suppressors. 21 Utilizing methodology and knowledge gained from the Human Genome Project, the TCGA project has therefore been mapping the human cancer genome since 2006. The TCGA project has been undertaken to investigate not only cancerrelated DNA abnormalities, but also methylation, mRNA, and protein expression abnormalities. [22] [23] [24] [25] [26] [27] Taken together, precision medicine is expected to be applied especially in the field of cancer, and aims to develop effective cancer treatment strategies by identifying genomic alterations in individual cancers. After a lengthy effort, it has been identified that target sequencing of the key genes in the cancer genome is one of the most effective ways to identify the characteristics of the disease, and to determine treatment strategies.
Although there are more than 20 000 genes in the human genome, the number of genes that are potentially related to cancer was found to be approximately 500, which includes driver-genes of can- 
| SAMPLE QUALIT Y CONTROL
To utilize panel testing in daily practice, it is crucial to preserve clinical samples in a suitable quality for the analysis (Figure 2 ). Although the NGS-based target sequence screening can suggest the most appropriate treatment for an individual patient, it is only possible in daily practice when commonly stored clinical samples are usable for NGS-based analysis. 28 In other words, the application of NGS-based analysis is only possible when DNA in preserved clinical samples is maintained in appropriate conditions with the production of minimal artifacts. 8 The majority of clinical samples from cancer patients, such as surgical specimens, are stored in formalin-fixed, paraffinembedded (FFPE) tissue, which can be used for DNA extraction and NGS analysis if processed and preserved appropriately ( Figure 2 ).
However, the reality is that DNA in FFPE tissue is often fragmented and unusable for NGS analysis. 29 DNA quality in FFPE tissue samples is often worse than expected, due to careless sample preparation and preservation. 8, 30 Therefore, it is critical for clinicians to know how to prepare and preserve samples for possible future NGS analysis. 8 Previously, we confirmed that neutral buffered formalin, but not unbuffered formalin, is suitable for fixation of surgical samples to preserve DNA adequately, in agreement with a previous report. 8, 31 It has been suggested that DNA damage occurs for the following reasons: formaldehyde-induced cross-linking; DNA fragmentation; deamination of cytosine bases leading to C->T mutations; and the generation of basic sites. 32 Furthermore, it is important for appropriate tissue preservation to fix for the appropriate time with formalin.
Over-fixation results in excessive cross-linking, thus interfering with the extraction of nucleic acids and proteins. 30 In contrast, underfixation causes degradation of nucleic acid and protein, or a change in gene expression in poorly formalin-perfused areas. 30 Furthermore, to avoid tissue ischemic changes, surgical specimens should be fixed with formalin immediately after removal of the specimen. 30 Taken together, an appropriate preservation procedure should be carried out in daily clinical practice, following a standard protocol with neutral buffered formalin to preserve high-quality DNA. Although DNA in FFPE tissue samples is as stable as in frozen samples, it will degrade over time. 33, 34 We found that DNA extracted from FFPE tissue samples of surgical specimens older than 7 years might not be analyzed by NGS. Clinicians should consider NGS analysis for cancer patients who are at a high risk of recurrence, sooner rather than later.
Biopsy samples can be very useful for NGS analysis. For instance, genomic analysis of tissue samples from biopsies will be useful for cancer patients who are treated with neoadjuvant chemotherapy, patients whose cancer is altered or diminished, or patients with nonresectable diseases. 35 Next generation sequence analysis could also provide clues for overcoming drug resistance using genomic data obtained from repeated biopsies for patients with tumor recurrence.
Although the amount of tissue in an FFPE biopsy sample can be very small, we have previously reported that DNA extracted from FFPE tissue from core needle biopsies of breast cancer or endoscopic biopsies of colorectal cancer can be available for NGS-based analysis.
In summary, utilizing FFPE samples of surgical specimens and biopsy tissue samples, NGS-based gene panel testing can be carried out if FFPE samples are appropriately preserved. Once again, it is important for clinicians to know how to preserve these samples. Next generation sequencing-based gene panel tests will provide useful information for cancer patients, which will be discussed in the following sections.
| WHAT DOE S AN NG S-BA S ED G ENE PANEL TE S T TELL YOU?
An NGS-based gene panel test can be used to identify gene alterations that are targetable by molecular-targeted drugs (Figure 3 ).
In the USA, a variety of NGS-based comprehensive gene panels have been developed, and some have been approved by the FDA as companion diagnostics for multiple molecular-targeted therapies ( Importantly, the targeted therapy will be effective not only to lung cancer patients, but also to other cancer patients with the ALK mutation. Moreover, RET is a targetable gene in non-small-cell lung cancer patients. Vandetanib, which targets RET rearrangements, showed clinical benefit in Japanese patients with advanced RET-rearranged non-small-cell lung cancer. 39 Therefore, comprehensive examination is effective for finding a specific population suitable for targeted therapy in all cancer patients.
Utilizing the gene panel test, we have also learned that we are able to detect not only the targetable driver-genes described above, but also mutations conferring drug resistance. Moreover, gene panel testing can be used to detect hypermutation, which is expected to
F I G U R E 2 Flow of a next generation sequencing (NGS)-based gene panel test utilizing formalin-fixed, paraffin-embedded (FFPE) tissue.
Preparation and preservation of FFPE tissue is the first step of the panel test, followed by DNA extraction, NGS analysis, curation of the data, and report of the data with therapeutic recommendations be a promising biomarker for immune checkpoint inhibitors. The comprehensive test further determines genetic changes in the DNA double-strand break repair pathway, which is an emerging target for new therapies, and also closely related to hereditary genomic changes. In the following sections, we discuss the application of gene panel testing, and issues that need to be addressed.
| TARG E T G ENE S OR RE S IS TAN CE-REL ATED G ENE S FOR MOLECUL AR-TARG E TED THER APY
In strategies involving precision medicine, selection of the most efficient treatment is based on identifying a subgroup of patients with certain characteristics in their genome. In addition to lung adenocarcinoma, another successful example of a treatment strategy involving precision medicine is anti-human epidermal growth factor receptor 2 (HER2) therapy using trastuzumab and other molecular- 
| MI CROSATELLITE IN S TAB ILIT Y AND HYPERMUTATION
Recently, the groundbreaking invention of immune checkpoint in- Recent progress in genomic analysis using NGS technology has allowed determination of the "mutation burden" in cancer. A hypermutated tumor is defined as a tumor with an increased mutation burden (a high rate of somatic mutation), which is associated with development of neoantigens and a response to immune checkpoint inhibitors. 27, [51] [52] [53] [54] The hypermutated cancer cells are thought to generate numerous neoantigens, which attract cytotoxic (CD8+)
T lymphocytes and activated Th1 cells to the tumor microenvironment surrounding cancer cells. 55 The mutation burden was initially determined by whole exome analysis, such as TCGA. 27 Later, utilizing the NGS-based panel test, we were also able to determine the tumor mutation burden, 8 which is expected to be very important in the field of immuno-oncology and cancer treatment.
The mutation burden can be defined as the rate of peptidechanging single-nucleotide variants per million base pairs. 56 To estimate the mutation burden, single-nucleotide variants with a mutation allelic fraction of at least 0.1 after standard filtering were retained. 56 We have previously reported that a panel test with 400 genes (roughly 
62,63
Detection of MSI is now considered important for the estimation of hypermutation, especially in colorectal and gastric cancer.
We found that 17 of 201 (8%) Japanese colorectal cancers were hypermutated tumors, as identified by a gene panel test. 8 Among them, we found 11 patients with MSI, and 2 patients with polymerase ε mutation, which is another cause of hypermutation. 8 We
Concept of "HER2-oma". Not only breast cancer patients, but also lung, gastric, and colorectal cancer patients with human epidermal growth factor receptor 2 (HER2) overexpression could be potentially treated with anti-HER2 therapies also identified 32 out of 207 (15.5%) Japanese gastric cancer patients as having hypermutated tumors, which were observed to be not only an MSI subtype, but also Epstein-Barr virus infection, which is detectable by integrative genomic analysis that makes use of NGS technologies, chromosomal instability, and genomically stable subtypes of TCGA. 11 In contrast, MSI is merely observed in breast cancer. We determined tumor mutation burden in triple-negative breast cancer patients and revealed that 3 of 51 (5.7%) patients were hypermutated. Other mechanisms rather than MSI, such as excessive APOBEC, might be involved in hypermutation in breast cancer, which needs further investigation.
| DNA DOUB LE-S TR AND B RE AK REPAIR PATHWAYS
One of the most promising targets that could be identified using the NGS-based gene panel test are genes related to homologous recombination (HR), which is one of the major mechanisms of DNA doublestrand break repair pathways. Cancer patients with a HR deficiency (HRD), of which the most notable ones are BRCA1/2 mutations, are more sensitive to PARP inhibitors. 64 Indeed, the US FDA have approved PARP inhibitors for patients with ovarian and breast cancer with a BRCA1/2 germline mutation. We examined BRCA1/2 mutations in a Japanese population and found alterations of BRCA1 and BRCA2 in 9.4% and 5.6% of Japanese TNBC patients, respectively, which is in agreement with previous reports.
There are several issues in detecting HRD in cancer patients.
First, there is a difficulty in interpretation of variants with unknown significance. Second, clinical significance of somatic mutations in HR genes are still not clear. 65 Somatic mutations of BRCA1/2 genes are observed in approximately 2.5% of all patients with sporadic breast cancer. 65 Theoretically, it is expected that somatic BRCA1/2-mutated breast cancers will respond to PARP inhibitors, similar to cancers with the germline mutation of those genes, however, it has not been conclusively shown that germline and somatic BRCA1/2 mutations are biologically equivalent. 65 Finally, although currently BRCA1/2 mutation status is the only biomarker to identify patients for PARP inhibitors, there are other genes that, when mutated, can lead to HRD.
64
However, the genes involved in HR are not yet well defined, and equal weighting might not estimate HRD appropriately. 65 Although it has been possible to determine mutations in HR-related genes utilizing NGS-based panel tests, a system to detect HRD by panel sequencing has not been established, partially due to the difficulty in estimating the HRD based on the related genes, as described above.
Germline mutation of BRCA1/2 can be a cause of familial cancer, such as breast, ovary, prostate, and pancreatic cancer, which is known as the hereditary breast and ovarian cancer syndrome.
Indeed, we found that 7 of 53 (13%) Japanese TNBC patients had possible germline BRCA1/2 alterations by additional bioinformatic analysis of solid tumor sequencing. Comprehensive genomic analysis utilizing gene panel tests revealed the frequency of BRCA1 and BRCA2 alterations to be 3.9% and 10.6% in Japanese gastric cancers, respectively. 11 Among them, we confirmed 3 patients with germline mutations and a family history, which indicates that BRCA1/2 germline mutations can be a cause of gastric cancer in Japan. 18 Considering the frequency of germline BRCA1/2 alterations in Japan, it appears that there is a certain population who would benefit from treatment with PARP inhibitors in Japan, not only in ovarian and breast cancer patients, but also others, potentially including gastric cancer patients.
| G EOG R APHI C AND E THNIC D IFFEREN CE S
An EGFR mutation, which is a predictive biomarker for clinical re- In colorectal cancer, HER2 amplification is significantly more common in Japan than in the TCGA cohort, which indicates a possibility for anti-HER2 therapy of colorectal cancer in patients screened by genetic testing in Japan. In breast cancer, there was significantly more MYC amplification in the TCGA cohort than in the Japanese cohort. In lung adenocarcinoma, mutations in CDKN2A, CDKN2B, and RB1, in addition to EGFR, were more common in the Japanese cohort than in the TCGA cohort. We found several differences between the Japanese cohort and the TCGA cohort or others, with the overall spectrum of genomic alterations similar among those populations.
Although drug response might be different, and we need to confirm the effect of new drugs for Japanese patients, it appears that we can utilize an NGS-based test to reveal genomic changes in cancer, in the same way as North America and European countries.
| ISSUE S TO B E ADDRE SS ED IN THE FUTU RE
Although NGS-based gene panel testing has the potential to change daily oncology practice, there are many issues to be addressed before it effectively saves cancer patients. One of the major issues of NGS remains the high cost. 67 The NGS-based gene panel tests cost several thousand US dollars per sample, depending on the vendor, and WES or whole genome sequencing cost more. Another major issue of NGS-based precision medicine strategies is lack of treatment. 68 The number of patients who find that their mutations are associated with a specific available treatment is limited. Clinical trials based on genetic panel tests is thought to be beneficial to the medical economy because it can narrow choice when selecting an expensive molecular-targeted therapy, and deliver it only to those in whom it is expected to be effective. is also expected as an application of liquid biopsy. 72 Although these techniques are expected to make it possible to measure tumor gene mutations in patients less invasively, as described above, there are still many problems to be solved at present, such as the reproducibility and accuracy of examination. This is especially so in breast cancer, as it is thought to be more difficult than carcinomas with many driver genes, such as colon cancer and lung cancer. There are also few genetic mutations that are common among patients, and the absolute number of circulating tumor cells in blood is much smaller than that of prostate cancer. It is expected that more convenient and useful tests will be developed as technologies progress.
| CON CLUS ION
In this review, we have described the utility of NGS-based gene panel testing and discussed issues that are a focus of future work. Cancer is a disease of the genome, and thus it is reasonable that treatment strategies should be based on genomic change. Although there are many issues that need to be addressed to fully realize precision cancer medi-
cine, it appears that we are generally headed in the right direction to improve a cancer patient's prognosis. It is important for clinicians to understand the utility of NGS-based genomic testing, as this will help the cancer patients of tomorrow, who are not currently able to be saved.
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